Intas corporate ppt

3,449 views
3,240 views

Published on

Published in: Business
0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
3,449
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Intas corporate ppt

  1. 1. Expressions for Healthy LifeINTAS GROUP OF COMPANIES
  2. 2. Corporate Overview We are… • A leading generic Pharmaceutical manufacturing and marketing company. Our Vision… • To become a leading global healthcare organisation driven by people, research and technologyINTAS GROUP OF COMPANIES
  3. 3. Journey So Far… 2009 Crossed 340 Mn USD turnover 2007 Supplies started to US 2006 New manufacturing facility in North and East India 2005 Commenced production of Cytotoxic products 2004 Acknowledged as one of the fastest growing pharma co. in India 2001 Laid foundation of Astron Research 2000 Setting up of the Bio-pharmaceuticals unit 1995 Set up an ultra modern manufacturing facility - Matoda 1984 Commences India Marketing Operations 1976 Intas sets up 1st manufacturing unitINTAS GROUP OF COMPANIES
  4. 4. Group Of Companies A leading pharmaceutical company in India Mfg Facility: Matoda, Vatva, DDN, SEZ, SIKKIM A Leading pharmaceutical A leading biotech company formulation and A leading clinical research in India & contract Marketing Arm of Intas development company organisation research company worldwide.INTAS GROUP OF COMPANIES
  5. 5. Astron Research Ltd. • Fastest growing Pharma Contract Research Organization • Accredited by USFDA • MHRA approved testing laboratory in UK • A team of 270 experienced scientist with inhouse fully equipped development laboratory. • Successfully developed 100+ products for regulated market. • Capabilities include Dossier Development, Formulation Research, Analytical Research, Regulatory Affairs & Quality Assurance • Expertise across various formulations like Solid Orals, Injectables, Lyophilised injectables, Topicals, Effervescent tablets & Oncology productsINTAS GROUP OF COMPANIES
  6. 6. Lambda Therapeutic Research Ltd. Lambda core activities: Facilities in: • Clinical trials (Phase I-IV) Ahmedabad 240 beds • BA & BE studies Mumbai 40 beds • 300 regulatory submissions in USA, Chennai 110 beds • Canada, EU, Australia, Brazil • Database of >25.000 volunteers Warsaw [ Poland ] 55 bedsINTAS GROUP OF COMPANIES
  7. 7. Intas Biopharmaceutical Ltd. • 1st EU approved Biotechnology facility in India • Having capabilities for manufacturing bio-recombinant and DNA based products, Ecoli & Cell culture based technology • Has successfully developed & launched recombinant proteins - Neukine (rHu G-CSF) - Erykine & Epofit (rHu EPO) - Intalfa (rHu IFN Alfa-2b) - Neupeg (Pegylated rHu G-CSF), - world’s first Peg Filgrastim after the innovatorINTAS GROUP OF COMPANIES
  8. 8. Manufacturing FacilitiesINTAS GROUP OF COMPANIES
  9. 9. Backward Integration… APIs • 1st eDMF : Gemcitabine • Others : Capecitabine, Paclitaxel, Docetaxel Temozolamide, Imatinib , Metoprolol Succinate, Telmisartan…….INTAS GROUP OF COMPANIES
  10. 10. Global FootprintsCANADA UK USA SPAIN VIETNAM MEXICO PERU INDIA (H.Q) BRAZIL KENYA SOUTH AFRICA AUSTRALIA NEW ZEALANDINTAS GROUP OF COMPANIES
  11. 11. Global Footprints • 11 ANDAs Approved, 18 filed, 45 ANDAs are in Development • 36 products approved. 20 dossiers filed in Europe. Additional 42 dossiers are in development • Holding 1100+ live registrations in 45 countries • Strong presence in Europe, Latin America, South Africa and Australia • Excellent contract manufacturing support for regulated markets 4.0 bn Tablets / Capsules manufactured during 2009 for EU 25+ satisfied partners Handling 100+ moleculesINTAS GROUP OF COMPANIES
  12. 12. Key Partners efiL yhtlaeH roF snoisserpxE CR PARTNERS Dossier Sale PartnersINTAS GROUP OF COMPANIES
  13. 13. INTAS GROUP OF COMPANIES
  14. 14. SITE LAYOUTINTAS GROUP OF COMPANIES
  15. 15. Oral solids Capacities Dosage Form Annual Capacity Regulatory Approvals Tablets & Capsules 5.2 Bn Tab / Cap USFDA Effervescent Tablets 300 Mn Tablets MHRA Narrow Therapeutic Tablets 900 Mn Tablets TGA Pellets 30000 Kgs ANVISA MCCINTAS GROUP OF COMPANIES
  16. 16. Injectables Capacities Dosage Form Annual Capacity Regulatory Approvals Liquid Ampoules 85 Mn MHRA Liquid Vials 30 Mn TGA MCCINTAS GROUP OF COMPANIES
  17. 17. Cytotoxic & Potent Dosages Capacities Dosage Form Annual Capacity Regulatory Approvals Tablets & Capsules 90 Mn Tab / Cap USFDA Liquid Vials 6.5 Mn Vials MHRA Lyophilized Vials 1.0 Mn Vials TGA ANVISA MCCINTAS GROUP OF COMPANIES
  18. 18. CAPACITIES – NEW FACILITY (SEZ) Dosage Form Annual Capacity Planned Approvals GENERAL MHRA (May. 10) Tablets & Capsules 6 Bn Tab/Cap USFDA (Date to finalize) ONCOLOGY Tablets & Capsules 200 Mn Tab/Cap Liquid Vials 10 Mn Vials Lyophilized Vials 8.0 Mn VialsINTAS GROUP OF COMPANIES
  19. 19. Intas : Your partner of choice for ….. • READY DOSSIERS FOR SUBMISSION TO ANVISA WITH OR WITHOUT COMMERCIAL SUPPLIES • DEVELOPMENT EXPERTISE THROUGH ASTRON FOR DEVELOPMENT OF BRAZIL DOSSIER FOR PRODUCTS OF YOUR INTEREST. • TECHNOLOGY TRANSFER OF THE PRODUCTS DEVELOPED BY ASTRON. • PRODUCT LISTINTAS GROUP OF COMPANIES
  20. 20. THANK YOU!INTAS GROUP OF COMPANIES

×